Exchange: BATS·Updated 07:34 PM EDT
News
all
press releases
MLTX Stock Under Pressure As Investors Await Psoriatic Arthritis Trial Data
MoonLake has consistently guided for a “mid-2026” primary endpoint readout from IZAR-1, its late-stage trial for sonelokimab in certain patients with active psoriatic arthritis.
Stocktwits
More News
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data
A Stocktwits user highlighted optimism for a buyout for MoonLake, highlighting other recent mergers and acquisitions in the pharma industry, such as Biogen’s buyout of Apellis.
Stocktwits
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event
Some Stocktwits users voiced optimism for the inflammation-drug maker getting acquired by pharma giant Merck.
Stocktwits
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations
BTIG upgraded MoonLake Immunotherapeutics to ‘Buy’ from ‘Neutral’ after the FDA said the company could show the effectiveness of Sonelokimab without additional HS trials.
Stocktwits
Why Did MLTX Stock Jump 45% In Pre-Market Today?
The company said it received positive regulatory feedback from the U.S. FDA following a Type B meeting regarding a drug used to treat hidradenitis suppurativa, a chronic inflammatory skin disorder.
Stocktwits

Advertisement|Remove ads.